

COMPLIMENTARY CME-CERTIFIED DINNER SYMPOSIUM

Evolving Concepts in Aortic Stenosis:

Emerging Evidence, Electronic Notifications,
and Optimal Lifetime Management

Sunday, November 8, 2026 | 5:30 – 7:30 PM CST

Marriott Marquis Chicago | Great Lakes BC, 2nd Floor



Scan to Register

Or go to: myCME.com/EvolvingTAVR

Program Description

Using an interactive case-based approach, the expert faculty will discuss contemporary evidence-based management strategies for patients with aortic stenosis (AS) who may be considered as candidates for transcatheter aortic valve replacement. The faculty will present common and challenging clinical scenarios to model optimal approaches to diagnostic evaluation, risk stratification, procedural planning, and longitudinal care—all informed by the latest clinical trials and registry data on outcomes of intervention in AS. The program will end with a live audience question-and-answer session.

Learning Objectives

- **Describe** the rationale for current investigations into the impact of aortic valve replacement in patients with moderate aortic stenosis (AS)
- **Address** potential obstacles to timely intervention in patients with moderate to severe AS
- **Evaluate** key considerations in lifetime management of AS, including long-term valve durability, safety, and efficacy data

Intended Audiences

General cardiologists, internal medicine, cardiology specialties such as heart failure, electrophysiologists who are physicians, advanced practitioners, or other healthcare professionals

Agenda

5:30 – 6:00 PM CST

Dinner/Registration

6:00 – 7:30 PM CST

Presentations and Interactive Discussions

Welcome and Introductions (Dr Lindman, Chair)

- Overview of Burden of AS, including moderate disease

Patient Case 1: Management of AS Across the Spectrum of Severity

- What Is the Impact of Intervention in Moderate AS? (Dr Genereux; all faculty)

Patient Case 2: Clearing the Patient Pathway to AS Treatment

- How can obstacles to timely intervention be overcome? (Dr Quader; all faculty)

Patient Case 3: Improving the Lifetime Management of AS

- What are the key considerations in choosing transcatheter vs surgical aortic valve replacement? (Dr Kaneko; all faculty)

Summary and Take-Home Messages (all faculty)

- Mitigating obstacles to optimal management (Expert guidelines; TARGET AS)
- Evidence for optimal treatment for moderate AS
- Long-term (7-10 years) outcomes/durability data



Supported by an educational grant from
Edwards Lifesciences, LLC.

Accreditation and Credit Designation Statements



In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians

Haymarket Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This event is not part of the official Scientific Sessions 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming.

Faculty



Brian R. Lindman, MD, MSc (Chair)

Medical Director, Structural Heart and Valve Center
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN



Philippe Génèreux, MD

Medical Director, Structural Heart Institute
Gagnon Cardiovascular Institute
Morristown Medical Center
Morristown, NJ



Tsuyoshi Kaneko, MD

John M. Shoenberg Chair of Cardiovascular Medicine
Division Director of Cardiothoracic Surgery
Washington University School of Medicine
Co-Director, Heart and Vascular Center
Barnes Jewish Hospital
St. Louis, MO



Nishath Quader, MD

Professor of Medicine,
Cardiovascular Division
Washington University School of Medicine
Barnes Jewish Hospital
St. Louis, MO